Genitourinary Radiology: Page 14

Cost-effectiveness study highlights MRI's value for prostate cancer biopsy

By Kate Madden Yee

Tuesday, November 30 | 3:00 p.m.- 4:00 p.m. | SSGU04-1 | Room E353CIn this Tuesday presentation, Dutch researchers will share findings from a study they conducted to explore the most cost-effective MRI biopsy strategy for men with suspected prostate cancer.

November 23, 2021

PET tracers can verify patient response to HIFU treatment

By Will Morton

Sunday, November 28 | 10:30 a.m.-11:30 a.m. | SSNMMI01-5 | Room N226In this molecular oncologic imaging presentation, researchers will report on the use of gallium-68-based radiotracers to assess response to high-intensity focused ultrasound (HIFU) therapy in prostate cancer patients.

November 22, 2021

Explainable artificial intelligence elevates prostate MRI reads

By Erik L. Ridley

Wednesday, December 1 | 8:00 a.m.-8:30 a.m. | SSGU05-4 | Room TBAAn explainable deep-learning software application can be highly accurate for characterizing prostate lesions on biparametric MRI exams, according to this scientific presentation.

November 14, 2021

Blue Earth highlights new Axumin research

By AuntMinnie.com staff writers

Bracco molecular imaging subsidiary Blue Earth Diagnostics is directing attention to new research that found PET/CT imaging with its Axumin PET radiopharmaceutical had a significant impact on management of patients with recurrent prostate cancer.

September 26, 2021

SNMMI updates appropriate use criteria for PSMA PET

By AuntMinnie.com staff writers

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has released new guidance for the clinical use of prostate-specific membrane antigen (PSMA)-PET imaging.

September 20, 2021

Lantheus touts Pylarify PET agent results at AUA meeting

By AuntMinnie.com staff writers

Lantheus Medical Imaging is directing attention to research presented at the recent 2021 American Urological Association (AUA) virtual annual meeting involving its Pylarify PET radiopharmaceutical (piflufolastat F-18).

September 9, 2021

PET tracer assesses response to new prostate cancer treatment

By Will Morton

PET imaging can identify whether or not patients respond to an investigational treatment for prostate cancer, according to a pilot study published in the September issue of the Journal of Nuclear Medicine.

September 7, 2021

PET/MRI better than MRI alone for detecting prostate cancer

By Will Morton

Functional imaging with PET/MRI is better than anatomic imaging alone for detecting prostate cancer in men who have a significantly higher chance of developing the disease, according to research published August 31 in Radiology.

September 3, 2021

Curium files IND application for prostate PET agent

By AuntMinnie.com staff writers

Nuclear medicine firm Curium has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for its copper-64 PSMA I&T diagnostic radiopharmaceutical.

August 23, 2021

Lightpoint, Telix ink collaboration agreement

By AuntMinnie.com staff writers

Luminescence imaging technology developer Lightpoint Medical has signed a collaboration agreement with radiopharmaceutical developer Telix Pharmaceuticals.

August 22, 2021

Anthem to cover Hologic's Acessa procedure for uterine fibroids

By AuntMinnie.com staff writers

Anthem Blue Cross will now cover Hologic's Acessa radiofrequency ablation procedure for treating uterine fibroids.

August 22, 2021

When is the best time to stop following low-risk prostate cancer?

By AuntMinnie.com staff writers

There are a variety of factors associated with the discontinuation of active surveillance of men with low-risk prostate cancer, both demographic and clinical, according to a study published August 20 in the Journal of Urology.

August 22, 2021

Previous Page

Page 14 of 93

Next Page